Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

ItalyBack to Italy

Clinical trials in Faenza – page 2

32 clinical trials in Faenza, Italy across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

ItalyOur site in ItalyStudi-Clinici.it(opens in a new tab)
Faenza at a glance
32
clinical trials
  • Paediatric trials0
  • Research sites1
Type of trial
Recruitment status
Quick filters

32 trials in Faenza

Open in trial search

Adenocarcinoma gastric

Not recruiting

Study of Tremelimumab and Durvalumab for Patients with Resectable Stomach or Gastroesophageal Junction Cancer with Microsatellite Instability

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:Fondazione GONO G.I.

Triple negative breast cancer

Not recruiting

Study on Avelumab for Patients with High-Risk Triple Negative Breast Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Avelumab
  • Sponsor:Universita Degli Studi Di Padova

Prostate cancer

Not recruiting

Study on Enzalutamide and Leuprorelin Acetate for Men with High-Risk Nonmetastatic Prostate Cancer After Treatment

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Enzalutamide
  • Sponsor:Medivation Inc.

Oesophageal squamous cell carcinoma

Not recruiting

Study of Atezolizumab and Tiragolumab for Patients with Unresectable Esophageal Squamous Cell Carcinoma After Chemoradiotherapy

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:F. Hoffmann-La Roche AG

Embolism venous

Not recruiting

Study Comparing Abelacimab and Apixaban for Preventing Blood Clots in Cancer Patients

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Abelacimab
  • Sponsor:Anthos Therapeutics Inc.

Embolism venous+1

Not recruiting

Study on Abelacimab and Dalteparin for Preventing Blood Clots in Patients with Gastrointestinal or Genitourinary Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Abelacimab
  • Sponsor:Anthos Therapeutics Inc.

K-ras gene mutation+2

Not recruiting

Study Comparing Divarasib, Sotorasib, and Adagrasib for Patients with Advanced or Metastatic KRAS G12C-Positive Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Sponsor:F. Hoffmann-La Roche AG

Cholangiocarcinoma

Not recruiting

Study Comparing Pemigatinib and Gemcitabine Plus Cisplatin for First-Line Treatment in Patients with Unresectable or Metastatic Cholangiocarcinoma with FGFR2 Rearrangement

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Cisplatin
  • Sponsor:Incyte Corp.

Colorectal cancer metastatic+1

Not recruiting

Study on the Safety and Effectiveness of Trifluridine/Tipiracil, Capecitabine, and Bevacizumab for Patients with Metastatic Colorectal Cancer Unfit for Intensive Chemotherapy

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Fondazione GONO G.I.

Malignant peritoneal neoplasm+2

Not recruiting

Study of Pembrolizumab for Patients with Recurrent, Platinum-Resistant Ovarian, Fallopian Tube, and Primary Peritoneal Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Malignant peritoneal neoplasm+2

Not recruiting

Study on Carboplatin, Paclitaxel, Bevacizumab, and Rucaparib for Advanced Ovarian, Primary Peritoneal, and Fallopian Tube Cancer Patients

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Transitional cell carcinoma

Not recruiting

Study on Nivolumab and Ipilimumab for Patients with Untreated Unresectable or Metastatic Urothelial Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Other cities in Italy

The busiest research cities in the country

All 237 cities in Italy

Clinical research in Faenza

What the registry says about research in the country

01 Oncology Research - Lung Cancer

Innovative clinical trials focusing on non-small cell lung cancer and small-cell lung cancer, evaluating novel combination therapies and targeted treatments.

  • Advanced NSCLC treatment studies
  • KRAS G12C mutation therapies
  • Immunotherapy combinations

Multiple studies examining maintenance therapies and first-line treatment options for lung cancer patients.

02 Gynecologic Oncology

Comprehensive research in ovarian cancer, including studies on maintenance therapies and novel treatment approaches for recurrent disease.

  • BRCA-related treatments
  • Advanced peritoneal cancer
  • Endometrial cancer therapies

Investigations into new therapeutic combinations and targeted treatments for gynecologic malignancies.

03 Gastrointestinal Cancer Research

Studies examining treatments for various gastrointestinal cancers, including innovative approaches for colorectal and gastric cancers.

  • Microsatellite instability studies
  • Biliary tract cancer treatments
  • Immunotherapy applications

Focus on personalized treatment approaches and combination therapies for GI tract malignancies.

Back to ItalyAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.